
Index

A

- Aachen Aphasia Test (AAT) test score, 80–81, 92
- α -Amino-3-hydroxy-5-methyl-4-isoxazoleproionic acid receptor (AMPA), 13, 15, 17
- Action Research Arm test (ARAT), 42, 45
- Activation volume index (AVI), 80, 81
- Activities of daily living (ADL), 44, 48, 122
- Aphasia, 187–188
 - neuroplastic changes and factors influencing, 89–91
 - neurorehabilitation of, 88
 - rTMS therapy
 - D&B quality checklist for, 97–98
 - GRADE system, 104–106
 - guidelines for clinical trials, 106–108
 - intervention studies for poststroke aphasia, 100–103
 - localization targets, 93–95
 - long-term evaluations, 95–96
 - non-RCTs, 97, 99
 - outcomes measures, 91–92, 106
 - patient criteria, 95–96
 - proof-of-concept treatment, 96
 - protocols, 92, 103, 106–107
 - RCTs, 96–97, 99
 - study duration and size, 108
- Aphasia Severity Rating Scale (ASRS), 92
- Aspiration pneumonia, 63
- Auditory cortex, 167, 169, 170, 176

B

- Barthel Index, 44, 48, 122
- Behavioral inattention test (BIT), 122
- Boston Diagnostic Aphasia Examination (BDAE), 91–92

- Brain-derived neurotrophic factor (BDNF), 13, 17, 59–60
- Brainsight® Neuronavigation system, 94
- Broca's aphasia, 80

C

- Calbindin (CB), 13, 16
- Catherine Bergego Scale, 122
- Cerebral metabolic rate for glucose (CMRGlc), 76
- Chronic pain syndrome, 148, 150, 167
- Cingulate cortex, 153
- Complex reaction time (CRT), 45
- Complex regional pain syndrome (CRPS), 151
- Constraint-induced movement therapy (CIMT), 32, 193
- Continuous theta burst stimulation (cTBS), 5, 40, 44–46, 58, 95, 118, 122, 124, 125, 192
- Conventional rTMS, 4, 5, 74
- Cortical excitability, 4, 7, 24–26, 28, 30, 40, 44, 49, 77, 131

D

- Dendritic spines, 13, 15–17
- Depression, 7, 105, 136, 139, 140, 166, 191
- Diaschisis, 31–32
- Dopamine, 130, 131, 138
- Dopamine replacement therapy, 130
- Dorsal premotor cortex (PMd), rTMS therapy in PD, 137–138
- Dorsolateral prefrontal cortex (DLPFC), 139, 140, 153, 154
 - high-frequency rTMS and low-frequency rTMS, combination of, 178
 - rTMS therapy in PD, 136–137

Downs and Black (D&B) tool, 97
 Dynamic causal modeling (DCM), 29
 Dysphagia, 188–189

- incidence, 63
- morbidity after stroke, 63
- post-stroke dysphagia, rTMS in, 64–65
- risk, 63–64
- rTMS application after stroke
 - clinical trials for treatment, 65–67
 - double-blind randomized controlled trails, 68
 - sham rTMS, 68

E

Electroencephalography (EEG), 167
 Electromyography, 24, 64

F

2-^[18F]Fluoro-2-deoxyglucose (FDG), 76
 Fiberoptic endoscopic evaluation of swallowing (FEES), 64, 65
 Fugl-Meyer, arm motor score (FM arm), 41, 46
 Functional magnetic resonance imaging (fMRI), 24, 30, 75, 79, 80, 82, 95, 117, 140, 175

G

GRADE system (Grading of Recommendations Assessment, Development, and Evaluation), 104–106, 124, 178

H

Headache, 47–49
 Hearing loss, 166–167, 177
 High-frequency stimulation. *See* Repetitive transcranial magnetic stimulation (rTMS)
 Hippocampal slice protocol, 2

I

Immediate early genes (IEG), 15
 Inferior frontal gyrus (IFG), 79, 92
 Interhemispheric competition model, 26–30, 187
 Interhemispheric inhibition (IHI), 27
 Ischemic brain lesion, 23

J

Jebsen Taylor hand function test (JTHF), 41

L

Language rehabilitation, 194
 Levodopa-induced dyskinesia (LID), 130

- abnormal synaptic plasticity, 138–139
- frontal brain areas, 139
- incidence, 138

 Long-interval intracortical inhibition (LICI), 25
 Long-term potentiation/depression (LTP/LTD), 2, 13, 15, 17, 23
 Low-frequency rTMS of the contralesional motor cortex (LF-rTMS), 40–43

M

Magnetoencephalographic (MEG), 167
 Malnutrition, 63–64
 Modified constraint-induced movement therapy (mCIMT) program, 193
 Motor cortex, 68, 153, 154, 157–158

- analgesic effects, 148–151
- contralesional, LF-rTMS of, 40–43, 51–53
- excitability, 24–26
- ipsilesional, HF-rTMS of, 43–44, 54
- primary, 3, 4, 7, 17, 131–136, 190, 192
- role in dysphagia, 64
- rTMS to lower limb function, 58
- theta-burst stimulation, 55–57

 Motor evoked potentials (MEPs), 3–4, 117, 153
 Motor rehabilitation, rTMS, 187

- BDNF genotyping, 59–60
- diaschisis, concept of, 31–32
- ‘inhibitory’/‘excitatory’ types of, 40
- interhemispheric competition model, 26–30
- ipsilesional motor cortical excitability effects, 24–26
- meta-analyses
 - adverse effect, 50
 - clinical decision making, 50–60
 - controlled and sham stimulation, 47
 - on cortical excitability, 49
 - effect sizes, 48–50
 - efficacy and safety of rTMS, 48
 - on hand function after stroke, 50
 - side effects, 47
 - sub-analyses report, 49
 - vs. systematic review, 48

- trials report, 48–49
 - on upper limb motor function, 49
 - period of time, 31
 - randomized controlled trials (*see* Randomized controlled trials (RCTs))
 - training-induced motor recovery, 59
 - treatment, 32–33
 - Motor symptoms, PD, 130, 138, 189
 - blinded randomized controlled studies, 132–134
 - clinical effects, 131
 - frontal areas, 137–138
 - prefrontal cortex, 136–137
 - primary motor cortex (M1), 132, 135–136
 - UPDRS part III, 131–132
- N**
- Neglect, 192. *See also* Visual hemineglect
 - after stroke, 188
 - definition, 115
 - incidence, 116
 - slower functional recovery, 115–116
 - Neural plasticity
 - cellular and molecular mechanisms of
 - rTMS-induced
 - in clinical practice, 18
 - effects during stimulation, 12–14
 - of excitatory synapses, 15–16
 - gene expression profiles, 17
 - inhibition and neuronal excitability, 16
 - in modulating network connectivity, 16–17
 - neuromodulators, 17–18
 - translation into clinical practice, 18
 - definition, 11–12, 23–24
 - forms of, 12, 14
 - role of, 12
 - Neurological diseases, 12, 15, 18
 - Neuromodulators, 17–18
 - Neuropathic pain, 190
 - motor cortex stimulation, 147–148
 - cortical targets, 154–155
 - mechanisms of action, 151–154
 - prevalence, 147
 - rTMS therapy
 - algorithm, 156
 - analgesic effects of motor cortex, 148–151
 - motor cortex stimulation, 147–148
 - period of time, 192
 - Neuroplasticity, 88
 - Neurorehabilitation program, 121
 - Neurostimulation, 69, 151, 155, 156
 - Neurotransmission, 16
 - NIH stroke scale (NIHSS), 41
 - Nine hole peg test (NHPT), 42
 - N-methyl-D-aspartate receptors (NMDARs), 13, 15, 17
 - Noninvasive brain stimulation (NIBS), 23, 40, 74, 78, 80, 82, 105, 107, 116, 130, 136
 - Non-motor symptoms, 130, 139–140
 - Nosie trauma, 166, 167
- O**
- Objective tinnitus, 166
 - Opponent processor model, 188
- P**
- Paired associative stimulation (PAS), 4
 - Paired-pulse TMS technique, 153
 - Parkinson's disease (PD), rTMS therapy, 189–190
 - further evidence, 140
 - levodopa-induced dyskinesia, 138–139
 - mechanisms of, 130–131
 - motor symptoms, 130, 138
 - blinded randomized controlled studies, 132–134
 - clinical effects, 131
 - frontal areas, 137–138
 - prefrontal cortex, 136–137
 - primary motor cortex (M1), 132, 135–136
 - UPDRS part III, 131–132
 - non-motor symptoms, 130, 139–140
 - period of time, 192
 - “weak recommendation,” evidence based, 140
 - Parvalbumin (PV), 13, 16
 - Patient with aphasia (PWA). *See* Aphasia
 - Patterned rTMS, 4, 92, 136
 - Penetration-aspiration scale (PAS), 69
 - Periaqueductal gray matter (PAG), 153
 - Plasticity, 131, 136. *See also* Neural plasticity; Synaptic plasticity
 - Positron emission tomography (PET), 24, 75–77, 80, 82
 - Posterior parietal cortex (PPC), 188
 - Poststroke aphasia (PSA), 74
 - effect of inhibitory rTMS, 79–82
 - functional imaging role, 76–77

- NIBS effect on recovery of, 78–79
recovery of, 79–82
- Psychiatric diseases, 12, 15, 18
- PsycINFO, 117
- PubMed, 117
- Q**
- Quadripulse stimulation (QPS), 4
- R**
- Randomized controlled trials (RCTs)
motor rehabilitation
HF-rTMS of ipsilesional motor cortex,
43–44, 54
LF-rTMS of contralesional motor
cortex, 40–43, 51–53
recovery of gait, 47
theta-burst stimulation, 44–46, 55–57
rTMS effect in PWA, 96–97, 99
rTMS for tinnitus treatment, 178
- Regional cerebral metabolic rate for glucose
(rCMRGlC), 75–76
- Repetitive transcranial magnetic stimulation
(rTMS), 88, 130. *See also specific
disease*
application in neurology, 185–186,
194–195
aphasia, 187–188
dysphagia, 188–189
motor rehabilitation, 187
neglect, 188
neuropathic pain, 190
Parkinson's disease, 189–190
period of time, 191–193
tinnitus, 190–191
cellular and molecular effects of, 12, 13
combinations of stimulation, 193–194
cortical reorganization, 23
effects on behaviour, 7–8
protocol for LTP-and LTD-like plasticity, 4
response variability, 5–7
and synaptic plasticity, 2–5
and training, 194
- Response variability, 5–7, 186
- Resting motor threshold (RMT), 7, 40, 49, 50,
99, 123, 135
- S**
- ScienceDirect, 117
- Serial target task (STT), 45
- Shorter simple reaction time (SRT), 45
- Short-interval intracortical inhibition
(SICI), 25
- Silent synapses, 17
- Speech and language therapy (SLT), 74, 79–80
- Spike timing-dependent plasticity (STDP), 2
- Stroke
aphasia (*see* Aphasia)
cerebral reorganization, 24–26
dysphagia (*see* Dysphagia)
functional imaging
functional and activation studies using
PET, 75–76
poststroke aphasia, 76–77
rTMS combination with, 77–78
incidence, 74
long-term disability, 39
malnutrition after, 63–64
motor rehabilitation (*see* Motor
rehabilitation, rTMS)
neglect (*see* Visual hemineglect)
neuropathic pain, 147–158
Parkinson's disease (*see* Parkinson's
disease (PD), rTMS therapy)
tinnitus (*see* Tinnitus)
- Subjective tinnitus, 166
- Supplementary motor area (SMA), rTMS
therapy in PD, 137
- Swallowing assessments, 64
- Synaptic plasticity, 2
in animal preparations, 4
and rTMS, 2–5
- T**
- Theta burst stimulation (TBS), 2, 4, 32, 44–46,
55, 92
- Tinnitus, 190–191
brain networks, 168
characteristics, 166, 190
classification, 166
cognitive behavioral therapies, 166
counseling, 166
fMRI and MEG studies, 175
hearing loss, 166
measurement, 169
neurobiology of, 190
occurrence, 166
pathophysiology, 167–168
phantom perception, 166–168
prevalence, 166
response to neuromodulatory approaches,
169

- rTMS therapy
 - application, 169
 - associated with emotional distress, 191
 - clinical effects, 169–170
 - Cochrane meta-analysis, 178
 - duration, 170
 - effect of low-frequency, 170, 178
 - FDG-PET data, 170, 175
 - high-vs. low-frequency rTMS, 191
 - neurobiological mechanisms, 175–176
 - quality of evidence, 178
 - repeated session effects, 170–174
 - safety aspects, 177
 - stimulation frequency, 170
 - stimulation target, 170, 175
 - sham treatments, 176–177
 - sound therapies, 166
 - TMS pulse (test pulse), 27
 - Transcranial magnetic stimulation (TMS)
 - basics of, 2–3
 - dysphagia after stroke, 64–65
 - neurorehabilitation of aphasia, 88
- U**
- Unbalanced interhemispheric inhibition (IHI), 187, 192
 - Unified Parkinson's Disease Rating Scale (UPDRS), 132
- V**
- Variability, response to rTMS, 5–7
 - Vicariation model, 26, 30, 187
 - Videofluoroscopic dysphagia scale (VDS), 69
 - Videofluoroscopy (VFS), 64, 65
 - Visual hemineglect
 - in acute stroke, 115
 - in copying Rey figure, 115, 116
 - definition, 115
 - incidence, 116
 - interhemispheric rivalry concept, 116–117
 - patient characteristics, 121
 - rTMS treatment, 116
 - case study report, 118–120
 - control conditions, 121
 - cTBS protocols, 118, 122–125
 - effect size calculation, 117–118, 122
 - example of, 122–123
 - level of evidence, calculation, 117–118
 - low frequency stimulation, 118, 122–123
 - methods, 117
 - neurorehabilitation program, 121
 - optimal stimulation protocol, 124
 - target stimulation, localization of, 121
- W**
- Wernicke aphasia, 79, 80
 - Western Aphasia Battery (WAB), 92
 - Wolf motor function test (WMFT), 41, 45, 46